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ABSTRACT
Insertion of a transgene into a defined genomic
locus in human embryonic stem cells (hESCs) is
crucial in preventing random integration-induced
insertional mutagenesis, and can possibly enable
persistent transgene expression during hESC ex-
pansion and in their differentiated progenies. Here,
we employed homologous recombination in hESCs
to introduce heterospecific loxP sites into the
AAVS1 locus, a site with an open chromatin struc-
ture that allows averting transgene silencing phe-
nomena. We then performed Cre recombinase
mediated cassette exchange using baculoviral vec-
tors to insert a transgene into the modified AAVS1
locus. Targeting efficiency in the master hESC line
with the loxP-docking sites was up to 100%.
Expression of the inserted transgene lasted for at
least 20 passages during hESC expansion and was
retained in differentiated cells derived from the gen-
etically modified hESCs. Thus, this study demon-
strates the feasibility of genetic manipulation at
the AAVS1 locus with homologous recombination
and using viral transduction in hESCs to facilitate
recombinase-mediated cassette exchange. The
method developed will be useful for repeated gene
targeting at a defined locus of the hESC genome.
INTRODUCTION
Human embryonic stem cells (hESCs) and induced pluri-
potent stem (iPS) cells have the unique ability to generate
virtually any differentiated cell type. In the context of re-
generative medicine, progenies derived from these human
pluripotent cells can be used as transplantable cells for
cell-based therapy. Many of such medical applications
would beneﬁt from continuous expression of therapeutic
transgenes after the genes are integrated into the genome
of the transplanted cells.
Random integration is currently commonly used to
introduce a transgene into hESCs and their progenies for
its stable expression. However, random integration can
result in insertional mutagenesis and subsequently tumori-
genesis of transplanted cells (1,2). Furthermore, expres-
sion of a randomly integrated transgene is unpredictable.
Integration within certain DNA sequence contexts can
trigger epigenetic silencing causing variegated expression
in clonally isolated cells or cessation of transgene expres-
sion to occur either over time or upon differentiation
(3–6). Hence, there is a compelling need to develop tech-
niques to integrate transgenes into a deﬁned genomic locus
that allows stable expression of the genes during expan-
sion and differentiation of hESCs without compromising
genomic stability.
Among different genomic sites tested, the adeno-
associated virus integration site 1 locus (AAVS1) is one
of the few loci that have been successfully targeted.
AAVS1 is located within the protein phosphatase 1, regu-
latory (inhibitor) subunit 12C (PPP1R12C) gene on
human chromosome 19 (19q13.3-qter). This site serves
as a speciﬁc integration locus for AAV serotype 2
(AAV2), a non-pathogenic human parvovirus (7).
AAVS1 has been characterized as a transcription-
competent environment comprising of an open chromatin
structure and contains native insulators that enable resist-
ance of the integrated genes against transgene silencing
(8–10). Since there is no known adverse effect on the cell
resulting from disruption of the PPP1R12C gene and the
transcriptional competence of a transgene cassette inserted
into the site remains across diverse cell types, AAVS1 is
considered as a ‘safe harbor’ for addition of a transgene
into the human genome (11).
To direct gene integration into AAVS1, AAV2 technol-
ogy using the AAV2 viral inverted terminal repeats (ITRs)
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had previously been employed in human somatic cells
(12–14). After incorporation of AAV2 ITRs and rep
genes into baculovirus, we showed before that transduc-
tion of the resulting baculovirus-AAV hybrid system in
hESCs led to stable transgene expression, but we were
unable to conﬁrm AAVS1 site-speciﬁc integration (15).
A plasmid transfection-based AAV2 technology was
later successfully used in hESCs for persistent transgene
expression, although site-speciﬁc integration at AAVS1
occurred at a low frequency of 4.16% (6). Recently,
zinc-ﬁnger nuclease (ZFN)-mediated homologous recom-
bination, a technique using ZFN-induced DNA
double-strand breaks to increase the rate of homologous
recombination (16), has been employed to direct trans-
genes into AAVS1, providing targeting efﬁciencies ranging
from 33% to 61% in hESCs and human iPS cells (17).
While attractive for gene function studies, the use of
ZFNs is still associated with cleavage at off-target sites
resulting in genotoxicity and cytotoxicity. This poten-
tial issue may complicate the therapeutic use of ZFN
technology (18).
Gene targeting by homologous recombination that uses
an extrachromosomal fragment of donor DNA
introduced into the cell, without pre-induction of DNA
double-strand breaks, has been tested in many different
cell types. However, homologous recombination fre-
quency is low in mammalian cells usually occurring in
one out of a million treated cells (16). For gene targeting
in hESCs, this conventional homologous recombination-
based technique has succeeded only in a limited number of
genomic loci so far (19–25). There are no reports as yet
on conventional homologous recombination-mediated
gene targeting at AAVS1, either in differentiated cells or
stem cells.
Over the years, the bacteriophage P1-derived Cre/loxP
system has proved to be an effective tool for genome
modiﬁcation in human cells owing to the high activity of
Cre recombinase in mammalian cells and its high degree of
DNA sequence speciﬁcity (26). This system has been used
for Cre recombinase-mediated cassette exchange
(Cre-RMCE) in which Cre recombinases target the loxP
sites and exchange a genomic fragment ﬂanked by a pair
of heterospeciﬁc loxP sequences for a ﬂoxed transgene
(ﬂanked by the same heterospeciﬁc loxP sequences).
RMCE has been performed at random genomic sites in
hESCs (27,28). When recombinase target sites are inserted
into a pre-deﬁned locus in the host cell genome by hom-
ologous recombination, RMCE can also be used to intro-
duce a desired transgene into the selected locus. With this
strategy, gene targeting has been performed at the
ROSA26 and HPRT loci in hESCs (21,22,25). RMCE ef-
ﬁciency is dependent on the relative and absolute
quantities of transgene DNA and recombinase present in
a cell. As demonstrated in differentiated somatic cells,
viral infection is signiﬁcantly more efﬁcient in mediating
RMCE than plasmid transfection (26).
To enable highly efﬁcient and safe gene targeting at
AAVS1 in hESCs, we adopted a two-step process in this
study. Homologous recombination was ﬁrst performed to
introduce heterospeciﬁc loxP sites into AAVS1, followed
by Cre-RMCE to introduce a ﬂoxed transgene in a site-
speciﬁc manner. In view of our previous ﬁnding that
baculoviral vectors are capable of transducing 80% of
hESCs with no observable cytotoxicity (15), we tested
whether baculoviral transduction-mediated Cre-RMCE
(BV-RMCE) could be used to improve integration
efﬁciency.
MATERIALS AND METHODS
Construction of plasmid and baculoviral vectors
To construct pBS-PGK-neo-lox,aAAVS1 targeting vector
used for homologous recombination, we ﬁrst induced a
two-base mutation within one of the loxP sites present
on PGKneotpAlox2 (Addgene, Cambridge, MA, USA)
that converts a loxP site into a lox2722 site containing a
new spacer sequence from the original ATGTATGC to A
AGTATCC. A 4kb left homology arm and 3kb right
homology arm pertaining to the PPP1R12C gene were
ampliﬁed from genomic DNA isolated from H1 hESCs
and cloned into pCR BluntII-TOPO (Invitrogen,
Carlsbad, CA, USA) independently. The two arms were
then excised using ClaI/XhoI and SacI/SacII, respectively,
and subcloned into the two ends of PGKneotpAlox2
comprising of the mutated lox2722 site, the phospho-
glycerate kinase promoter (PGK), the neomycin resistance
gene (neo) and the wild-type loxP site. Primers used in this
study are listed in Supplementary Table S1.
To prepare baculoviral vectors for BV-RMCE, 1kb Cre
ORF was ampliﬁed from pBS185 (Addgene) and pFB-
EF1a-Cre was constructed by inserting the Cre ORF
into a pFastBac1 vector previously developed in the lab
(15) using HindIII to replace its original 0.7kb EGFP
ORF. To construct pFB-EF1a-EGFP-neo-lox, 2.1kb
fragment containing the elongation factor-1 alpha pro-
moter (EF1-a), the EGFP gene and a SV40 poly(A) tail
was ampliﬁed from pFB-EF1a-EGFP and cloned into
the mutated PGKneotpAlox2 construct using EcoRI. A
4.9kb fragment comprising of the mutated lox2722 site,
the EF1a promoter, the EGFP gene, the neomycin resist-
ance gene and the wild-type loxP site was then excised
from this construct and cloned in to pFastBac1 using
NotI/SalI. To construct pFB-EF1a-EGFP-hyg-lox,
1.6kb fragment comprising of the SV40 promoter, the
hygromycin resistance gene (hyg) and a SV40 poly(A)
tail was ampliﬁed from pDsRed-Monomer-Mem Hyg
(Clontech, Mountain View, CA, USA) and used to
replace the fragment containing the PGK promoter and
the neomycin resistance gene in pFB-EF1a-EGFP-neo-lox
using BlpI/PﬂMI. To construct pFB-EF1a-HSVtk-hyg-
lox, 1.4kb fragment containing the HSVtk suicide gene
and a SV40 poly(A) tail was ampliﬁed from a construct
previously developed in the lab (29) and used to replace
the fragment comprising of the EGFP gene and the SV40
poly(A) tail in pFB-EF1a-EGFP-hyg-lox using AfeI/SbfI.
Recombinant baculoviruses were propagated using the
Bac-to-Bac Baculovirus Expression System (Invitrogen).
Recombinant DNA research in this study followed the
National Institutes of Health guidelines.
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H1 hESCs (WiCell, Madison, WI, USA) were cultured in
feeder-free conditions in compliance with the protocol
stated in the technical manual: ‘Maintenance of hESCs
in mTeSR
TM10 (StemCell Technologies, Vancouver, BC,
Canada). For homologous recombination, 2 10
6 hESCs
were transfected 4 days following subculture with 2mgo f
BsaI linearized pBS-PGK-neo-lox at a 1:3 DNA to reagent
ratio (FuGENE HD Transfection Reagent, Roche,
Mannheim, Germany). G418 selection (50mg/ml, Gibco)
in mTeSR1 medium started 48h after transfection.
Medium was changed daily for 3 weeks until resistant
colonies propagated. For RMCE, 2 10
6 loxP-hESC2
cells were transduced 4 days following subculture with
BV-EF1a-Cre at a MOI of 100. Twenty-four hours later
the medium was changed and cells were again transduced
at a MOI of 100 with either BV-EF1a-EGFP-hyg-lox or
BV-EF1a-HSVtk-hyg-lox. Hygromycin B selection (25mg/
ml, A.G. Scientiﬁc, San Diego, CA, USA) in mTeSR1
medium started 48h after the second viral transduction.
Medium was changed daily for 4 weeks. Each colony,
propagated through either G418 or hygromycin B selec-
tion, was transferred to a single well of a Matrigel-coated
6-well plate and allowed to undergo clonal expansion
without drug selection. One week later, each clone was
subcultured at 1:6 ratio. DNA of the clones was isolated
(DNeasy Blood and Tissue Kit, Qiagen, Hilden,
Germany), and screened for AAVS1 locus modiﬁcation
through PCR and Southern blot analysis.
Stem cell differentiation and characterization of
differentiated cells
The protocols for formation and maintenance of neuro-
spheres and differentiation of adherent neural stem cells
(NSCs) in to astrocytes and neurons have been previously
reported (30,31). Mesenchymal stem cells (MSCs) and den-
dritic cells were generated as previously reported (32,33).
Primary monoclonal antibodies tested for ﬂow cyto-
metric analysis of EGFP-MSCs include phycoerythrin
(PE)-conjugated anti-CD24, anti-CD34, anti-CD45, anti-
CD44, anti-CD73, anti-CD90, anti-CD105 and anti-
CD166, allophycocyanin (APC)-conjugated anti-HLA
ABC, FITC-conjugated anti-HLA DRQP and their re-
spective isotypes (BD Pharmingen, San Diego, CA,
USA). After primary antibody incubation, cells were
washed and further stained with a TRITC-conjugated sec-
ondary antibody (Sigma-Aldrich, St Louis, MO, USA).
For EGFP-DC analysis, primary monoclonal antibodies
tested were APC-conjugated anti-CD11c, anti-CD40,
anti-CD45, anti-CD86, anti-CD209 and their respective
isotypes (BD Pharmingen). Before analysis of EGFP-
hESCs, dead cells were excluded through PI staining
(Sigma-Aldrich). Cells were analyzed using a
FACSCalibur
TM ﬂow cytometer (BD Biosciences).
For RT–PCR analysis, total RNA was extracted with
TRIzol (Invitrogen) and cDNA was synthesized using
the SuperScript III First-Strand Synthesis System
(Invitrogen). Ampliﬁed products were analyzed on a 2%
agarose gel.
For immunostaining of differentiated glial cells and ne-
urons, primary monoclonal antibodies tested include anti-
GFAP (Sigma-Aldrich) and anti-bIII tubulin (Promega).
Detection of Oct-3/4, SOX2, Nanog and SSEA-4 in
EGFP-hESC1 was done using the hESC Marker
Antibody Panel Plus (R&D Systems, MN, USA). The
secondary antibody used was a Texas Red-conjugated
secondary antibody (Abcam, Cambridge, MA, USA).
In vitro tumor killing and migration assay
For in vitro tumor killing assays, neurospheres were
dissociated and seeded at 1 10
3cells/well on a
Matrigel-coated 96-well plate. U87 cells were seeded into
the same plate at 1 10
3cells/well. NSC medium contain-
ing ganciclovir (Invivogen) at 20mM was added the fol-
lowing day and changed every alternate day for 1 week. A
cell viability assay was performed using the CellTiter 96
AQueous One Solution (Promega) and absorbance was
read using a Benchmark Plus
TM microplate spectropho-
tometer (Bio-Rad).
The migration ability of TK-NSC was determined using
the BD Falcon
TM HTS FluoroBlok
TM 96-Multiwell Insert
System (8mm pore size, BD Biosceinces). U87 cells were
seeded in the bottom receiver plate at 6.4 10
4cells/well
in Opti-MEM I (Invitrogen). NSCs, labeled with
Calcein-AM (AnaSpec), were seeded in the inserts at
2.5 10
4cells/insert. After incubation for 24h, the ﬂuor-
escence emitted from the top (corresponding to non-
migrating cells) and bottom (corresponding to migrating
cells) sides of the plate was measured using a GENios
Pro
TM microplate reader (Tecan, Ma ¨ nnedorf, Switzerland).
RESULTS
Generation of loxP-hESC lines
The use of the Cre/loxP system for the integration of
transgenes within a speciﬁc locus initially requires the in-
sertion of loxP-docking sites within that particular locus
through homologous recombination. To target AAVS1 on
chromosome 19 (19q13.42), we constructed a targeting
vector pBS-PGK-neo-lox containing a ﬂoxed neomycin
resistance marker ﬂanked by a left and right arm corres-
ponding to  7kb of homology of the PPP1R12C gene.
Exon 1 (337bp) of the gene is present in the left arm while
exons 2 (131bp) and 3 (119bp) are present on the right.
AAVS1 begins 424bp upstream of the 50-end of exon 1
and ends 3.35kb downstream of the 30-end. The region
that we targeted is  1.9kb downstream of the 30-end of
exon 1 (19:60318479–19:60318512) and can also be con-
sidered as intron 1.
Following three independent transfection experiments
with pBS-PGK-neo-lox in feeder-free culture condition, a
total of 39 hESC colonies emerged after G418 selection
(Table 1). The DNA of these clones was subjected to PCR
genotyping by using a primer speciﬁc for the PGK promoter
present on the pBS-PGK-neo-lox construct and a primer
speciﬁc for chromosome 19 downstream of the 30-end of
the right homologous arm. The ampliﬁcation of 3.3kb
fragment indicated a modiﬁed AAVS1 (Figure 1A and B).
Through this analysis, 11 clones, out of 39, were identiﬁed
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Southern blot analysis was performed on three randomly
selected loxP-hESC clones (Clones #2, #5 and #6) using a
probe speciﬁc for chromosome 19. The detection of 9.8kb
fragment indicated a modiﬁed AAVS1, as opposed to the
detection of 7.1kb fragment that indicates the intact locus
(wild-type). Fragments of both sizes were detected thereby
identifying the clones to be heterozygous (Figure 1C and D).
loxP-hESC Clone #2 (loxP-hESC2) was used as a master
loxP-hESC line subjected to further downstream
applications.
Cre recombinase-mediated cassette exchange using
baculoviral vectors
Once a loxP-hESC line was generated, it was subjected
to Cre-RMCE. We generated two baculoviral vectors,
BV-EF1a-Cre to express Cre recombinase and BV-
EF1a-EGFP-hyg-lox as the transgene donor. The consti-
tutive EF1a promoter was used to facilitate transgene
expression in both un-differentiated and differentiated
states. BV-RMCE was then performed in loxP-hESC2
using the two viral vectors. Two days after transduction,
cells were subjected to hygromycin B selection for 4 weeks.
Most of the cells died off in the ﬁrst week. Small colonies
remained in the second week, which expanded in the third
and fourth week. Following three independent transduc-
tion experiments, a total of 33 EGFP-hESC colonies
stably propagated in feeder-free culture condition through
hygromycin B selection (Table 1). The DNA of these
clones was subjected to PCR genotyping by using one
primer speciﬁc for chromosome 19 and another speciﬁc
for the EF1a promoter present in BV-EF1a-EGFP-hyg-
lox. The ampliﬁcation of 4.2kb fragment indicated the in-
tegration of the EGFP gene within AAVS1 by BV-RMCE.
Through this analysis, 30 EGFP-hESC clones were
identiﬁed as having undergone site-speciﬁc integration at
AAVS1 (Figure 2A and B; Supplementary Figure S1).
We also conﬁrmed that the transduction of wild-type
hESCs (wt hESCs) with BV-EF1a-Cre and BV-EF1a-
EGFP-hyg-lox and also the transduction of loxP-hESC2
with BV-EF1a-EGFP-hyg-lox alone yielded no colonies
through hygromycin B selection (unpublished observa-
tion). These results indicate that loxP sites within the gen-
ome and the expression of Cre recombinase are both
necessary for BV-RMCE.
To dismiss the possible existence of multiple EGFP gene
copies within the clones, Southern blot analysis was per-
formed on all the EGFP-hESC clones using a probe speciﬁc
for the EGFP gene. The detection of 3.8kb fragment
indicated the integration of the EGFP gene within AAVS1
and the inability to detect fragments of other sizes indi-
cated the absence of random integration. This analysis
conﬁrmed that all 30 EGFP-hESC clones that were identi-
ﬁed as having undergone site-speciﬁc integration through
the PCR analysis contained only one EGFP gene copy
(Figure 2C and D; Supplementary Figure S2). The
EGFP-hESC clones that lack 4.2kb fragment in PCR
analysis (Clones #3, #12 and #17 in Supplementary
Figure S1) also contained one EGFP gene copy as revealed
by Southern blotting, but showed distinct band pos-
itions that clearly differed from that of 3.8kb in length
(Figure 2C), suggesting random chromosome integration
of the cassette in the three clones. EGFP-hESC Clone #1
(EGFP-hESC1) with a single copy of the EGFP gene at
AAVS1 was used for downstream characterizations.
AAVS1 locus-directed transgene integration results in
stable expression in hESCs
Six hours after baculoviral transduction, we started to
observe EGFP-positive hESCs. But most of the
Table 1. Efﬁciencies of gene targeting by homologous recombination and gene insertion by BV-RMCE at AAVS1 in hESCs
Homologous recombination Exp1 Exp2 Exp3
No. of transfected cells 2000000 2000000 2000000
No. of G418 resistant colonies 12 9 18
No. of correctly targeted colonies veriﬁed by PCR analysis 3 4 4
No. of correctly targeted colonies veriﬁed by Southern blot analysis 3 nd nd
Homologous recombination frequency as veriﬁed by PCR analysis 1.5 10
 6 2.0 10
 6 2.0 10
 6
Targeting efﬁciency as veriﬁed by PCR analysis (%) 25.00 44.44 22.22
Mean targeting efﬁciency (%)±SD 30.56±12.11
BV-RMCE for EGFP-hESC Colonies Exp1 Exp2 Exp3
No. of hyg B resistant colonies 9 18 6
No. of correctly recombined colonies veriﬁed by PCR analysis 8 16 6
No. of correctly recombined colonies veriﬁed by Southern blot analysis 8 16 6
Site-speciﬁc integration efﬁciency (%) 88.89 88.89 100
BV-RMCE for TK-hESC Colonies Exp4
No. of hyg B resistant colonies 4
No. of correctly recombined colonies veriﬁed by PCR analysis 4
Site-speciﬁc integration efﬁciency (%) 100
Mean BV-RMCE efﬁciency (%)±SD 94.45±6.41
Exp, experiment; PCR, polymerase chain reaction; nd, not determined.
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EGFP-negative cells in the ﬁrst 2 weeks of drug selection.
Drug-resistant EGFP-positive colonies emerged after 2
weeks of selection and EGFP-positive cells increased
over time (Figure 3A). By 4 weeks, the hESC colonies
appeared almost entirely green. Flow cytometric analysis
revealed that 99.82% of EGFP-hESC1 collected 3 weeks
after stopping drug selection was EGFP-positive
(Figure 3A and B). The EGFP transgene in the selected
hESCs maintained stable expression at the same intensity
for at least 20 weeks over 20 passages (Figure 3B).
Two EGFP-hESC clones that underwent random inte-
gration (Clones #3 and #12) were also subjected to hygro-
mycin B selection. Similar to hESC colonies with the
EGFP gene integrated into AAVS1, pure EGFP-
expressing hESC populations were obtained from the
two clones after 4 weeks of drug selection. However,
after stopping drug selection, we observed a decrease in
EGFP expression as early as 7 weeks after drug selection.
Flow cytometric analysis indicated that transgene silenc-
ing occurred in 30–35% of the selected hESCs within
7 weeks following the withdrawal of drug selection
and a signiﬁcant portion of the EGFP-expressing cells
displayed low ﬂuorescence intensity (Figure 3C).
Our results are consistent with previous reports that
random integration of transgenes is subject to silencing
that leads to variegated transgene expression (3–5) and
conﬁrm that integration within AAVS1 does in fact
result in persistent gene expression (6,11,17).
AAVS1 locus-directed transgene integration had no effects
on hESC pluripotency
As revealed by RT–PCR analysis, EGFP-hESC1 conti-
nued to express pluripotent markers, but not ectoderm,
mesoderm and endoderm markers (Figure 4A).
Immunostaining also demonstrated the expression of sev-
eral pluripotent marker proteins in EGFP-hESC1 (Figure
4B and Supplementary Figure S3), further conﬁrming the
undifferentiated state of these genetically modiﬁed hESCs.
To investigate whether EGFP-hESC1 retain their ‘stem-
ness’ property, embryoid bodies were derived from these
cells (Figure 5A) and the expression of germ layer markers
was analyzed through RT–PCR. We observed the expres-
sion of ectoderm, mesoderm and endoderm markers,
but not pluripotent markers in the embryoid bodies
(Figure 4A). We further demonstrated that neurospheres
could be derived from EGFP-hESC1 (Figure 5B) and the
Figure 1. Homologous recombination to generate loxP-hESCs. (A) Schematic of AAVS1 within the PPP1R12C gene, the targeting vector, and the
modiﬁed AAVS1 with heterospeciﬁc loxP sites following homologous recombination. e1, e2 and e3: the ﬁrst three exons of the the PPP1R12C gene.
(B) PCR analysis for detection of the modiﬁed AAVS1. loxP-hESC clones are identiﬁed through ampliﬁcation of 3.3kb fragment as indicated in (A).
(C) Southern blot analysis to detect the modiﬁed AAVS1. Following digestion with ApaLI and hybridization, two fragments (7.1kb and 9.8kb as
indicated in D) are detected in loxP-hESC clones (Clones #2, #5 and #6) opposed to the solitary fragment detected in wild-type (wt) hESCs. This
result indicated that the loxP-hESC clones were heterozygous, comprising of one intact AAVS1 and one modiﬁed locus. (D) Schematic representation
to show the position of the probe used for Southern blot analysis.
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neuro-progenitor markers when compared with hESCs
(Figure 4C). These neurospheres could further differenti-
ate into b-III tubulin-positive neurons and GFAP-positive
glial cells (Figure 5D and E). Cells generated from differ-
entiation of EGFP-hESC1 toward mesenchymal lineage
(Figure 5F) exhibited a surface marker proﬁle character-
istic of MSCs, including CD44, CD73, CD90, CD105 and
CD166, but did not express markers characteristic of hem-
atopoietic progenitor cells, including CD24, CD34 and
CD45 (Figure 4D). Through Co-culturing of EGFP-
hESC1 with OP9 stromal cells, we generate hematopoietic
progenitor cells from EGFP-hESC1, which were further
differentiated into dendritic cells (Figure 5G). Flow
cytometric analysis indicated that these cells expressed
CD86, CD40, CD11c and CD209, the markers character-
istic of dendritic cells, and also CD45, a marker charac-
teristic of hematopoietic lineage (Figure 4E). These results
conﬁrm that the differentiation potential of EGFP-hESC1
is not compromised by transgene integration into AAVS1.
Persistent transgene expression maintained after
hESC differentiation
While examining whether EGFP-hESC1 can differentiate
into multiple cell lineages, we also observed persistent
expression of EGFP in differentiated progenies of the
Figure 2. Baculoviral transduction to introduce the EGFP gene into AAVS1 in loxP-hESCs. (A) Schematic representation of the generation of an
EGFP-hESC line through BV-RMCE. loxP-hESC2 with a modiﬁed AAVS1 was transduced with two baculoviral vectors for site-speciﬁc transgene
integration. (B) PCR analysis for detection of site-speciﬁc transgene integration. EGFP-hESC clones that underwent site-speciﬁc integration are
identiﬁed through ampliﬁcation of 4.2kb fragment indicated in A. (C) Southern blot analysis to detect site-speciﬁc transgene integration and EGFP
gene copy number. Following digestion with NcoI and hybridization, a solitary fragment (3.8kb) is detected in most of EGFP-hESC clones with
site-speciﬁc integration. A fragment of dissimilar size is detected in EGFP-hESC Clones #3, #12 and #17, which underwent random integration. (D)
Schematic representation to show the position of the probe used for Southern blot analysis.
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was no decline in EGFP expression during the formation
of embryoid bodies and their maintenance (Figure 5A).
Neurospheres derived from EGFP-hESC1 and cul-
tured for 4 weeks displayed no loss of EGFP ﬂuorescence
(Figure 5B). Through RT–PCR analysis, expression
of EGFP mRNA was conﬁrmed in neurospheres derived
from EGFP-hESC1, but not from wt hESCs (Figure 5C).
EGFP-hESC1-derived, terminally differentiated glial
cells and neurons continued to express the transgene
(Figure 5D and E). EGFP-hESC1-derived MSCs and
dendritic cells were cultured for 2 weeks after differenti-
ation and still displayed bright EGFP expression.
Quantiﬁcation by ﬂow cytometric analysis indicated that
92–98% of these differentiated cells were EGFP positive
(Figure 5F and G).
Glioma gene therapy potential of hESC-derived
neural stem cells after a transgene integrated
into AAVS1 in hESCs
To demonstrate the potential clinical application of
BV-RMCE, we generated a hESC line expressing the
A
B
C
Figure 3. Stable transgene expression after AAVS1 integration. (A) EGFP expression as demonstrated with ﬂuorescence imaging in EGFP-hESC1, a
hESC clone, in which AAVS1 integration of the EGFP transgene was conﬁrmed. Cell samples photographed before, during or after drug selection are
shown. (B) EGFP expression quantiﬁed using ﬂow cytometric analysis of EGFP-hESC1. The cells were collected 3 or 20 weeks after stopping drug
selection for analysis. (C) EGFP expression in EGFP-hESCs of Clones #3 and #12 with random integration of the EGFP transgene. The cells were
collected and analyzed 7 weeks after stopping drug selection.
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from the master loxP-hESC2 line (Figure 6A). The
HSVtk/ganciclovir system, a commonly used cancer gene
therapy regime, uses HSVtk-phosphorylated ganciclovir
to inhibit DNA replication, thus inducing tumor cell
death (34). HSVtk-phosphorylated GCV molecules may
further display bystander killing effect by diffusing to
nearby tumor cells. Four colonies were propagated
through hygromycin B selection. The DNA of these
clones was subjected to PCR genotyping using a primer
speciﬁc for chromosome 19 and a primer speciﬁc for the
HSVtk gene present on the baculovirus carrying the
EF1a-HSVtk-hyg-lox cassette (BV-TK). The ampliﬁca-
tion of 3.5kb fragment indicated the integration of the
HSVtk gene within AAVS1. Through this analysis, all
four clones were identiﬁed as having undergone site-
speciﬁc integration (Figure 6B and Table 1). TK-hESC
Clone #1 (TK-hESC1) was selected randomly and sub-
jected to neural differentiation. RT–PCR analysis con-
ﬁrmed the expression of HSVtk in TK-hESC1 and
derived NSCs (TK-NSCs), but not in NSCs derived
from wt hESCs (wt NSCs, Figure 6C).
We then tested whether TK-NSCs had the ability to kill
cancer cells through bystander effects by mixing U87
human glioma cells with TK-NSCs or wt NSCs
transduced with BV-TK at 1:1 ratio in a co-culture system.
We observed that wt NSCs, after transient transduction
with BV-TK, killed 55.93±4.51% of the mixed cells in
the presence of ganciclovir. TK-NSCs, however, had an
ability to kill 86.74±4.64%. The enhanced killing efﬁ-
ciency of TK-NSCs was attributed to the stable expression
of HSVtk, as opposed to the transient expression found in
baculoviral transduced wt NSCs (Figure 6D).
NSCs are capable of migrating toward tumors and thus
can be used in the Trojan horse approach as cellular
vehicles for targeted delivery of therapeutic genes to
distant tumor sites (35,36). To test whether TK-NSCs
derived from the genetically modiﬁed hESCs display any
tumor tropism, we conducted an in vitro migration assay
using Boyden chambers. TK-NSCs displayed a high mi-
gration capacity toward U87 glioma cells: the percentage
of migrated cells was up to  70%, while the percentage of
cells migrating toward plain Opti-MEM cell culture
medium was <30% (Figure 6E). The strong tropism of
A
C
B
DE
Figure 4. Maintenance of phenotype and pluripotency in genetically modiﬁed EGFP-hESCs. (A) RT–PCR analysis of pluripotent markers and stem
cell lineage markers in EGFP-hESC1 and derived embryoid bodies. Note that EGFP-hESC1 expresses pluripotent markers Oct-3/4 and Nanog while
EGFP-embryoid bodies express ectoderm markers Pax6 and NeuroD, mesoderm marker Brachyury and endoderm marker AFP. (B) Immunostaining
to detect the expression of pluripotent markers Oct-3/4, Sox2, Nanog and SSEA-4 in EGFP-hESC1. (C) Molecular characterization of
ectoderm-derived cells. Neurospheres derived from EGFP-hESC1 and wild-type hESCs were used for RT–PCR analysis. Neurospheres derived
from both hESC lines are positive for SOX2 and nestin as well as display an upregulation of neural progenitor marker SOX1 when compared with
EGFP-hESC1. (D) Flow cytometric characterization of mesoderm-derived cells. MSCs derived from EGFP-hESC1 are positive for all ﬁve MSC
markers CD44, CD73, CD90, CD105 and CD166 as well as for HLA-ABC. They are negative for hematopoietic progenitor markers CD24, CD34
and CD45 as well as for HLA-D(RQP). (E) Flow cytometric characterization of dendritic cells derived from EGFP-hESC1. Cells are positive for DC
markers CD11c, CD40, CD86 and CD209 as well as for hematopoietic lineage marker CD45.
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still functionally adequate for tumor targeting after
site-speciﬁc genetic modiﬁcation at AAVS1.
DISCUSSION
Previous studies have demonstrated gene targeting at
AAVS1 in hESCs using AAV2 and ZFN technologies
(6,17). To circumvent some potential limitations asso-
ciated with the two methods, we have in the current
study developed the third method for such genetic
modiﬁcation using a two-step process combining homolo-
gous recombination with BV-RMCE. Although two
time-consuming steps were used in our approach at the
beginning, the generated master loxP-hESC line provides
rich opportunities for readily introducing transgenes into
A C
B
D
F
G
E
Figure 5. Maintained transgene expression in differentiated progenies of EGFP-hESCs after AAVS1 integration of a transgene. EGFP expression is
retained in EGFP-hESC1-derived embryoid bodies (A), neurospheres (B and C), GFAP-positive glial cells (D), b-III tubulin-positive neurons (E),
MSCs (F) and dendritic cells (G). Results from RT–PCR analysis of EGFP-hESC1, neurospheres derived from EGFP-hESC1 (EGFP-NSC) and
NSCs derived from wild-type hESCs (wt NSC) are shown in (C). Results from quantitative ﬂow cytometric analysis of EGFP-hESC1-derived MSCs
and dendritic cells are shown on the right in (F) and (G), respectively.
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ciency in the master hESC line by our BV-RMCE tech-
nique could be close to 100%, which is much higher than
that provided by the AAV2 technology. The method does
not use an enzyme to introduce DNA double-strand
breaks and thus could be less complicated in being
translated into clinical applications. Furthermore, by
integrating the HSVtk suicide gene within AAVS1,w e
obtained a genetically modiﬁed functional NSC popula-
tion possessing tumor migratory properties as well as the
ability to induce gap-junction-mediated bystander killing
effects in glioma cells, thereby demonstrating the clinical
application potential of the genetic modiﬁcation approach
developed in this study.
Gene targeting through homologous recombination is
difﬁcult to achieve in hESCs, primarily due to low clonal
efﬁciency and low gene transfer efﬁciency (37). So far,
only several genes, including POU5F1, HPRT1,
ROSA26, Fezf2 and Olig2, have been successfully
targeted in hESCs by natural homologous recombination,
with varying targeting efﬁciencies ranging from as low as
1.5% to as high as 40% (19–25). We demonstrated here
for the ﬁrst time gene targeting at AAVS1 in hESCs by
conventional homologous recombination without intro-
duction of DNA double-strand breaks. A homologous re-
combination frequency of 2 10
 6 was achieved in
hESCs, with a targeting efﬁciency of 30.56±12.11%
when our AAVS1 targeting vector pBS-PGK-neo-lox
Figure 6. Baculoviral transduction to introduce the HSVtk suicide gene into AAVS1 in loxP-hESCs and the use of derived NSCs for cancer therapy.
(A) Schematic representation of the generation of a TK-hESC line through BV-RMCE. loxP-hESC2 with a modiﬁed AAVS1 was transduced with
two baculoviral vectors for site-speciﬁc transgene integration. (B) PCR analysis for detection of the integration of the HSVtk gene into AAVS1.
TK-hESC clones that underwent site-speciﬁc integration are identiﬁed through ampliﬁcation of 3.5kb fragment. (C) RT–PCR analysis to detect
HSVtk expression in TK-hESC1 cells and dervied NSCs. (D) Cell viability analysis following in vitro tumor killing. Each group consisted of 10
repeats and values are expressed as mean±SD. *P<0.05 versus the U87+wt NSC group by an unpaired t-test. (E) Migration of TK-NSCs toward
U87 glioma cells. Each group consisted of seven repeats and values are expressed as mean±SD. *P<0.05 versus the migration toward Opti-MEM
by an unpaired t-test.
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were tested with pBS-PGK-neo-lox to generate G418 re-
sistant colonies. After picking 50 clones, we identiﬁed 18
clones (36%) comprising of a modiﬁed AAVS1 (C. J. A.
Ramachandra et al. unpublished observations). However,
when using a long construct, pBS-EF1a-EGFP-neo-lox
with the identical homology arms, for integration of the
EGFP gene and the neomycin resistance gene within
AAVS1 simultaneously through homologous recombin-
ation, the frequency decreased by >3-fold (1 out of 11
clones). This result indicated that apart from the
homology arms, targeting efﬁciency is also inﬂuenced by
the sequence of the integrated gene and its regulatory
elements present in the targeting construct. It is likely
that using homologous recombination to integrate a
large transgene together with a cellular promoter into
the AAVS1 locus would be a challenging task, even
when the homologous arms are available.
Through the use of ZFN-mediated homologous recom-
bination, the targeting efﬁciency at AAVS1 is greatly
enhanced (17). However, the efﬁciency of this system is
dependent on the type of ZFN pair used as demonstrated
with the targeting of the POU5F1 locus (17). Also, the
induction of off-target DNA breaks at related sequences
throughout the genome could lead to potentially hazard-
ous effects (18). Hence, by generating a loxP-hESC line
through natural homologous recombination and develop-
ing the BV-RMCE method, we have provided a safer al-
ternative for efﬁcient gene targeting at AAVS1 in hESCs.
The use of baculoviral vectors for the delivery of Cre
recombinase and the ﬂoxed transgene in hESCs is justiﬁed
by several factors. Previously, the use of lentiviral vectors
was shown to achieve high transient transduction efﬁ-
ciencies as well as induce stable transgene expression in
hESCs (38,39). However, these vectors achieve stable
transgene expression by integrating randomly within the
genome. Although possessing a lower risk of random in-
tegration, commonly used adenoviral vectors and AAV2
vectors were shown to achieve low transduction efﬁci-
encies in hESCs (40). A study comparing gene transfer
efﬁciencies between the use of viral and non-viral vectors
in hESCs showed that the use of electroporation and
lipofection were the least effective methods at <3% (41).
Baculoviral vectors on the other hand are able to trans-
duce up to 80% of hESCs with no observable cytotoxicity
(15,42). Baculoviral vectors derived from Autographa
californica multiple nucleopolyhedrovirus (AcMNPV) rep-
licate in insect cells, but become replication incompetent
in mammalian cells, providing a property that makes them
easy for production and far less harmful in clinical use.
When used for genetic modiﬁcation of human cells,
baculoviral vectors, unlike lentiviral vectors, mediate
transgene expression without integration into the host
genome and the virus DNA degrades quickly within
transduced mammalian cells (43), thus suiting the purpose
of temporary transgene expression well. These features of
baculoviral transduction decrease the probability that
baculoviral vectors used ex vivo and transgene products
expressed from the vectors will invoke undesired immune
responses after the genetically engineered cells are trans-
planted into the body. This hypothesis, however, needs to
be tested in future studies. Nonetheless, the safety of the
occluded Heliothis zea baculovirus has been evaluated
with feeding tests on volunteer human subjects and clinical
tests showed no signs of inﬂammation, allergy or side
effects (44). The use of baculovirus also presents other
advantages such as a large cloning capacity to accommo-
date a DNA insert up to 38kb (45), rapid construction of
recombinant baculovirus using routine cloning methods
and easy preparation of high-titer viruses. All these
features will contribute to the successful application of
baculovirus-mediated RMCE for genetic engineering of
hESCs.
The Cre/loxP system has been used previously in attain-
ing genetic modiﬁcation in hESCs (21,22,25,27,28).
Through the use of a cell-permeable Cre recombinase a
highly efﬁcient site-speciﬁc recombination frequency was
achieved in hESCs (27). However, apart from demon-
strating the recombination inducing ability of the Cre to
delete an integrated transgene, this research did not use
any system to integrate transgenes into a speciﬁcally
deﬁned locus through RMCE. RMCE mediated by the
cell-permeable Cre recombinase has later been used for
gene insertion after screening to select transgene
silencing-resistant hESC lines with one integration copy
of a built-in loxP exchange cassette (28). As shown in
the study, a site-speciﬁc targeting efﬁciency of  33%
was achieved and in the rest of the selected clones cell-
permeable Cre recombinase mediated either non-speciﬁc
recombination or random integration. In differentiated
somatic cells, the Cre/loxP system has been combined
with the use of adenoviral vectors to successfully induce
RMCE (26). However, a major drawback with this adeno-
virus system was that RMCE was only successful in cells
that supported adenoviral replication because a high copy
number of viral vectors within the cell are required.
Obviously, any sort of viral replication within transplant-
able cells is precarious and hence their use in the clinical
setting is undesirable. On the other hand, due to the high
transduction efﬁciency of our baculoviral vectors in
hESCs, the use of BV-RMCE in the current study to in-
tegrate the EGFP gene and the HSVtk suicide gene within
AAVS1 resulted in site-speciﬁc targeting efﬁciencies of
92.59±6.42% and 100%, respectively (Table 1). This
result further conﬁrms the limited random integration
ability of baculovirus in hESCs.
Looking ahead, the method developed in the current
study has made the repeated transgene insertion at
AAVS1 possible, presenting the opportunity for intro-
ducing various therapeutic genes safely into the genome
of hESCs or human iPS cells for medical applications.
Generation of human iPS cells from patients’ cells allows
for cell transplantation therapy free from immune rejec-
tion. An alternative approach is to establish an iPS cell
bank with various human leukocyte antigen (HLA) types.
We envision that our technology can be applied to human
iPS cells and even be used to establish a small bank of
modiﬁed iPS cells with common HLA types and hetero-
speciﬁc loxP sites at the AAVS1 locus. Using a cell type-
or lineage-speciﬁc promoter in our BV-RMCE vectors, it
should also be possible to integrate transgenes into
AAVS1 in the progenies derived from a master pluripotent
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biological studies to understand gene function in early
human development and cell type differentiation, the
master cell line can be used for long-term expression of
shRNAs in a uniform chromatin landscape for functional
comparison of different genes.
With the AAVS1-modifed hESCs as a starting material
for generating transgenic hESC, the time spent on labori-
ous screening of modiﬁed hESC clones will be signiﬁcantly
reduced. AAV2 is a common human virus. A recent study
using an unbiased genome-wide analysis of wild-type
AAV2 integration revealed that the integration sites are
scattered throughout the human genome, with only 10%
of total integration hotspots being identiﬁed within the
AAVS1 locus (46). Thus, targeted integration of
wild-type AAV2 is not as speciﬁc as previously assumed
for the AAVS1 locus. Moreover, since genetic modiﬁca-
tion with homologous recombination and RMCE will
interrupt the AAVS1 site in one of two homologous chro-
mosomes 19 (as shown by our Southern blot analysis), the
site does not remain intact any longer in the modiﬁed
hESCs. We speculate that the disrupted site will have sig-
niﬁcantly reduced functionality as a wild-type AAV2 in-
tegration site, further reducing the chance of deleterious
interaction of wild-type AAV2 with the integrated
transgene.
In conclusion, the key contributions of the current study
include conﬁrming the feasibility of homologous recom-
bination at AAVS1, demonstrating the high efﬁciency of
baculovirus-mediated RMCE in hESCs, and developing a
two-step process combining homologous recombination
with baculovirus-mediated RMCE for site-speciﬁc genetic
modiﬁcation of hESCs. The technology holds potential to
advance the ﬁeld of stem cell research.
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